Methods for identification of sites for IgG conjugation
The present disclosure relates to immunoglobulins and immunoglobulin conjugates with reduced oligomerization and efficient labeling and compositions, methods of generating such immunoglobulins and immunoglobulin conjugates and methods of using such immunoglobulin conjugates particularly in the treatment and prevention of disease.
1. An immunoglobulin conjugate, comprising an immunoglobulin having at least one mutation at 7(VH), wherein the residue numbering for the immunoglobulin is according to Kabat numbering, wherein the at least one mutation is a substitution with a cysteine residue, and an atom or molecule, wherein the atom or molecule is conjugated to the cysteine residue.
2. The immunoglobulin conjugate of claim 1 , further comprising a linker molecule having at least two reactive sites, wherein a first reactive site is bound to the cysteine residue of the immunoglobulin and a second reactive site is bound to the atom or molecule.
3. The immunoglobulin conjugate of claim 2 , wherein the linker molecule is selected from the group consisting of a hydrazone, a peptide, a chelating agent, and a maleimide.
4. The immunoglobulin conjugate of claim 1 , wherein the atom or molecule is selected from the group consisting of a radionuclide, a chemotherapeutic agent, a microbial toxin, a plant toxin, a polymer, a carbohydrate, a cytokine, a fluorescent label, a luminescent label, an enzyme-substrate label, an enzyme, a peptide, a peptidomimetic, a nucleotide, an siRNA, a microRNA, an RNA mimetic, and an aptamer.
5. The immunoglobulin conjugate of claim 1 , wherein the atom or molecule is selected from the group consisting of 90 Y, 131 I, 67 Cu, 177 Lu, 213 Bi, 211 At, a calicheamicin, a duocarmycin, a maytanisoid, an auristatin, an anthracyclin, Pseudomonas exotoxin A, Diphtheria toxin, ricin, polyethylene glycol, hydroxyethyl starch, and a mannosyl residue.
6. A pharmaceutical composition comprising the immunoglobulin conjugate of claim 1 and a pharmaceutically acceptable excipient, wherein at least eighty percent, at least eighty-five percent, at least ninety percent, at least ninety-five percent, at least ninety-six percent, at least ninety-seven percent, at least ninety-eight percent, or at least ninety-nine percent of the immunoglobulin conjugate is non-oligomerized monomer.
7. The pharmaceutical composition of claim 6 wherein the immunoglobulin conjugate is at a concentration of at least 10 mg/ml, at least 20 mg/ml, at least 30 mg/ml, at least 40 mg/ml, at least 50 mg/ml, at least 75 mg/ml, at least 100 mg/ml, at least 125 mg/ml, or at least 150 mg/ml.
8. The immunoglobulin conjugate of claim 2 , wherein the linker molecule forms a disulfide linkage with the cysteine residue.